ALK and non-small cell lung carcinoma: To evaluate the diagnostic performance of cfDNA‐NGS, we analyzed the detection rate of ALK alterations by cfDNA‐NGS in the ALK rearranged NSCLC patients who had been diagnosed by ALK IHC, FISH, or targeted NGS from tumor tissue.